PBLS

Sinker

Parabilis Medicines, Inc. · Healthcare · United States · $3.4B cap · $27.2M/day traded

$27.44 -0.7% · close 20 Nov · scored 21 Nov

Sinker: Weak business, rich price and weak momentum. Nothing here to keep it afloat.

4
Score
Get score and insider alerts
Quality
18
Value
24
Momentum
27

As of 21 Nov 2026, the MoatMap Score for Parabilis Medicines, Inc. (PBLS) is 4/100, ranked against 25,000+ stocks in 38 markets (Quality 18, Value 24, Momentum 27, each scored against its sector).

Does the score work? Each tenth of the ranking, tracked monthly. See the record →

P/E (TTM)
—
peers 25.6x
ROE
—
peers -30.1%
D/E
0.0x
peers 0.2x
Dividend %
—
trailing yield

ABOUT PARABILIS MEDICINES, INC.

Read

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.

FINANCIAL SUMMARY (USD)

Year20242025TTM2026E2027EFwd CAGR
Income and shares
Revenue———3.4M4.0M—
Net marginn/mn/m————
EPS-2.0-1.8-3.6-2.6-2.4—
Share count118.1M118.1M123.7M———
Balance sheet
Debt66.2M58.7M41.8M———
Equity56.4M-16.5M————
Debt/equity1.2xn/m————
Cash flow
Op. cash flow-103.6M-123.7M-120.8M———
Cash flow marginn/mn/m————
Investing CF30.2M39.8M————
Financing CF78.1M64.4M————

Cash on hand equals about 7.2 years of the operating cash used in the last twelve months. Spending on equipment or exploration and any new funding are not counted.

PRICE (1Y) · USD-5.2%
22.824.726.628.530.412 Oct2 Nov20 Nov
SMA 50SMA 200

Price checkNo read yetExperimental

Not enough steady price history for a read yet.

How this is worked out

The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.

  • Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
  • Finding a floor: It fell hard, but has set no new low for more than two weeks.
  • Turning up: It has climbed off its low and is back above a rising 50-day average.
  • In an uptrend: It is near its 52-week high and above its 200-day average.
  • No clear trend: None of the above: no recent deep fall and no steady climb.
  • No read yet (this stock): Not enough price history yet: it needs a year of trading.

In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.

The exact rules

Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.

In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.

Rules fixed before any data was fetched. Describes the chart, not a recommendation.

Close
$27.44
RSI (14)
50.7

SCORE BREAKDOWN

Quality
18
ROIC
-751.6%0.9
ROE
—N/A
GP/Assets
-189.3%0.2
Op. Margin
-8509.8%1.9
FCF/Assets
-151.6%1.2
Piotroski
29.3
Int. Cover
-50.0x5.8
D/E Ratio
0.04x72.7
Current Ratio
12.88x91.8
Value
24
P/E (TTM)
—N/A
EV/EBITDA
-13.7x25.0
P/FCF
—N/A
P/B
3.4x35.4
P/S
1519.5x1.5
Div Yield
—N/A
Momentum
27
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
-7.3%8.7
EPS Rev 12W
-23.5%7.1
EPS Improve
+35%68.3
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$3.4B
P/E (Forward)
-11.7x
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PBLS are excluded.

TickerCompanyMkt CapScore
PBLSParabilis Medicines, Inc.(you)$3.4B4
VKTXViking Therapeutics, Inc.$3.2B7
IONSIonis Pharmaceuticals, Inc.$4.4B2
DYNDyne Therapeutics, Inc.$2.9B11
RCUSArcus Biosciences, Inc.$2.2B6
COGTCogent Biosciences, Inc.$4.6B9
CELCCelcuity Inc.$2.6B9
TNGXTango Therapeutics, Inc.$3.7B16
BEAMBeam Therapeutics Inc.$2.2B9
VERAVera Therapeutics, Inc.$1.8B7

Peer medians: ROE -30.1% · P/E 25.6x · Gross margin 63.4%

Company Deep Dive

A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.

Request Deep Dive(50 Feathers)

Parabilis Medicines, Inc. (PBLS): Stock Score Summary

Parabilis Medicines, Inc. (PBLS) has a MoatMap Score of 4/100 based on Quality (18/100), Value (24/100), and Momentum (27/100) factor scores.

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.

Director dealings

From 22 Nov 2025 to 20 Nov 2026, MoatMap's records hold no sales and 7 purchases of Parabilis Medicines, Inc. (PBLS) shares by its directors. The largest: RA CAPITAL MANAGEMENT, L.P. bought 21,188,750 shares at $20.00 on 11 Jun 2026 (about $423.8M).

  • 22 Jul 2026: RA CAPITAL MANAGEMENT, L.P. bought 47,250 shares at $29.77 (about $1.4M)
  • 21 Jul 2026: RA CAPITAL MANAGEMENT, L.P. bought 65,923 shares at $29.25 (about $1.9M)
  • 20 Jul 2026: RA CAPITAL MANAGEMENT, L.P. bought 131,420 shares at $27.28 (about $3.6M)
  • 15 Jun 2026: SEBULSKY ALAN bought 9,065 shares at $26.49 (about $240K)
  • 12 Jun 2026: SEBULSKY ALAN bought 8,435 shares at $27.67 (about $233K)
PBLS insider filings, last 180 days

Key Financial Metrics

Price$27.44
Market Cap$3.4B
P/E (Forward)-11.69
Price/Book3.38
Return on Invested Capital-751.6%
Debt/Equity0.04x
Operating Margin-8509.8%
Free Cash Flow$-123M

Parabilis Medicines, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Parabilis Medicines, Inc.’s (PBLS) MoatMap Score?
The MoatMap Score for Parabilis Medicines, Inc. (PBLS) is 4/100. It is a composite of Quality (18), Value (24), and Momentum (27), each scored against its sector. The composite is then ranked across MoatMap’s universe of 25,000+ stocks.
Does Parabilis Medicines, Inc. have an economic moat?
Parabilis Medicines, Inc. (PBLS) has a Quality factor score of 18/100. Quality blends several measures of profitability and financial strength, led by gross profit to assets, return on invested capital and free cash flow to assets. A high score describes the financial record a durable advantage tends to leave; it does not prove a moat.
What sector is Parabilis Medicines, Inc. in?
Parabilis Medicines, Inc. (PBLS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).